FDA allows clinuvel’s innovative vitiligo trial. For this trial, the company has made the announcement on Thursday March 3rd, 2011. This announcement for the trial widely known with the terminology, ‘FDA allows clinuvel’s innovative vitiligo trial’ was made at Baar, Switzerland and in Melbourne, Australia.

The American-European inspired trail is to start rolling on at the leadings centers spread across the globe. As per the reports, the Clinuvel Pharmaceuticals Ltd earlier made the announcement that the American food and drug administration known with the abbreviation FDA has allowed the enterprise to go under its present investigational New Drug in order to hold a pilot phase II clinical trial (CUV 101) of its drug afamelanotide found in the patients who are diagnosed with the disease of vitiligo.

It is being said that that this trial known as ‘FDA allows clinuvel’s innovative vitiligo trial’ would be for the very first time tested as a repigmentation remedy in the patients with nonsegmental vitiligo, which happens to be a pigmentary disorder widely affecting the patients around more than 45 million patients
worldwide). And this trial would be done as part of the Clinuvel’s Inspire Program.

It is vivid that the disease of Vitiligo is what that leaves the white patches on the skin of a human and these patches may spread all over the body in bigger and large circles. These patches emerge on the skin because of the lack of melanin which is also called pigment. The disease may result in patient’s psychological and emotional distress.

The location of the trial known as ‘FDA allows clinuvel’s innovative vitiligo trial’ would be at six sites across the US (California, Michigan and New York) and Europe (France, Italy and Switzerland). The duration of this trial would be twelve months (one year) – revolving around six months of treatment of the patient and then the remaining six months of follow up.